Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Charles Coombes, MD, PhD, on Clinical Implications of Using Samuraciclib With Fulvestrant for HR–Positive HER2–Negative Breast Cancer

Posted: Tuesday, March 8, 2022

Charles Coombes, MD, PhD, of Imperial College, London, discusses what the results of his research on a first-in-class, oral, selective inhibitor of CDK7 used in combination with fulvestrant could mean for patients with advanced hormone receptor–positive, HER2– negative breast cancer who have progressed on their prior CDK4/6 inhibitor treatment.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.